Athersys, Inc has been granted patent in US for stem cell technology that has potential to treat heart attack, stroke, inflammatory bowel disease etc.
The U.S. patent 7,659,118 covers non-embryonic multipotent stem cells, their isolation and expansion, and related pharmaceutical compositions, Athersys announced.
Athersys’ proprietary scalable MultiStem technology is an investigational stem cell therapy that has demonstrated therapeutic potential to treat a broad range of diseases and indications, including acute myocardial infarction, inflammatory bowel disease (IBD), bone marrow transplant support and ischemic stroke.
MultiStem cell therapy product consists of a special class of stem cell that is obtained from bone marrow or other tissue sources of healthy, consenting adult donors, and which has the demonstrated ability to produce a range of factors and form multiple cell types.
MultiStem appears to promote tissue repair and healing in multiple ways, such as through the production of multiple therapeutic factors produced in response to signals of inflammation and tissue damage.
Athersys is currently developing MultiStem therapy inflammatory bowel disease (IBD) together with Pfizer as part of a strategic partnership announced in December 2009.
Similary, Athersys is partnering with Angiotech to develop MultiStem in acute myocardial infarction and other cardiovascular indications.
“These patents further expand our stem cell IP estate and offer additional validation of the strength and breadth of the Athersys IP portfolio,” said William (B.J.) Lehmann, president and COO of Athersys.
The patents are especially important as they extend the coverage of the composition, isolation, differentiation and scalable manufacturing of non-embryonic stem cells that are core to Athersys’ technology and product portfolio, he added.
Athersys has also been granted — and the opposition period has cleared — EP patent EP1218489B1 that covers non-embryonic pluripotent stem cells, their isolation, expansion, and usage.
Both patents form part of Athersys’ broad intellectual property (IP) portfolio of 14 granted patents and more than 120 global patent applications around its stem cell technology and MultiStem product platform.
The current IP estate, which incorporates additional filings and may broaden over time, could provide coverage for Athersys’ cell compositions, methods of use, manufacturing processes, and product candidates through as late as 2028.
MultiStem represents is a “off-the-shelf” stem cell product. MultiStem has the ability to deliver multiple mechanisms of therapeutic benefit, to be administered without tissue matching or immunosuppression, and to be produced on a large-scale.
In 2008, Athersys was awarded the Frost & Sullivan North American Product Innovation of the Year Award for MultiStem, which cited the product as having best-in-class potential among stem cell and regenerative medicine technologies.
Athersys is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life.
The company is developing MultiStem, a patented, adult-derived “off-the-shelf” stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation and oncology treatment support, ischemic stroke, and inflammatory bowel disease.
Athersys is also developing a portfolio of other therapeutic programs, including orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE).
Athersys has forged several key strategic alliances and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions in the United States and Europe to further develop its platform and products.